From the poster, under 1903, for his description of ‘PDT’....

From the poster, under
1903, for his description of ‘PDT’.
Conclusions



The phase 2 trial safety criteria are being met regarding the sensitiser doses, plus the laser light energy delivery and equipment. Normal bladder and bowel function has been maintained and as well, unaltered erectile potency has been recorded. A stable or decreasing PSA has been recorded in 15/21 patients treated > 6/12. Prostate size reduction has also been recorded. Quantitative scientific pre and post treatment proteomic results of cancer necrosis, inflammation, vascular and significant immune responses have confirmed those of the Phase 1 study. This PDT trial in the 21st Century describes a user friendly, chlorophyll-based PS with potential application to a variety of malignant cell types. The trial continues the assessment of PDT, an orphan in the EMR therapeutic realm, of radiotherapy and radio frequency ablation(RFA). While remembering that Dr Niels Finsen was awarded the Nobel prize in 1903, for his description of ‘PDT’.

That's the holy grail, activation of the immune system and for IVX043, triggering the immune system memory effect.

GLTA